Why It Matters
Dr. Erica Schwartz’s confirmation as director of the Centers for Disease Control and Prevention hinges on narrow Republican support in a divided Senate committee. Her testimony revealed significant daylight between her positions and those of key lawmakers, casting doubt on her path to Senate approval and raising questions about public health priorities under the Trump administration.
What Happened
Schwartz, a retired Navy admiral and former deputy surgeon general, testified before the Senate Health, Education, Labor and Pensions Committee on Wednesday. The hearing lasted more than two hours, with questions ranging from vaccine safety to disease reporting protocols.
Committee Chairman Bill Cassidy, a Louisiana Republican and physician, pressed Schwartz repeatedly about whether she would follow the example of former CDC Director Susan Monarez, who was fired last year after refusing to pre-approve vaccine recommendations and declining to remove career officials at the agency’s request. Cassidy told Schwartz he believed administration officials had over-prepared her for the hearing and that some of her responses fell short. “I felt like you were always trying not to answer my question, which was disappointing,” Cassidy said.
On core public health questions, Schwartz affirmed established scientific consensus. She testified that vaccines do not cause autism and that messenger RNA vaccine technology is safe and effective. However, she appeared evasive on disease reporting obligations when questioned about the Trump administration’s decision to make cyclosporiasis reporting optional in July 2025. Senator Patty Murray, a Washington Democrat, cited over 7,000 confirmed or under-investigation cases and more than 100 hospitalizations linked to the outbreak. Schwartz acknowledged she was unaware of the reporting change and declined to commit to reinstating mandatory reporting requirements.
Other Republican senators signaled competing priorities. Senator Josh Hawley of Missouri asked Schwartz to commit to investigating health implications of living near data centers and to ensure the CDC secures state-by-state abortion data, which the agency collects through a voluntary reporting system.
By the Numbers
12-11 — Republican advantage on the committee
7,000+ — Confirmed or under-investigation cyclosporiasis cases cited by Senator Murray
100+ — Cyclosporiasis hospitalizations cited by Senator Murray
July 2025 — When the Trump administration made cyclosporiasis reporting optional
Zoom Out
The Schwartz hearing reflects broader Republican divisions over public health agency autonomy and scientific messaging. The collapse of the Monarez tenure last year demonstrated that ideological conflict over vaccine recommendations and personnel decisions continues to reshape the CDC’s governance. Schwartz’s nomination test is whether a consensus candidate can satisfy both Republicans concerned about institutional independence and those seeking greater executive control over agency messaging and operations.
Disease surveillance reporting has become a point of contention across administrations. The shift to optional cyclosporiasis reporting drew criticism from epidemiologists concerned that voluntary systems miss cases and impede outbreak response, a dynamic that surfaced during Schwartz’s hearing.
What’s Next
The committee must vote on Schwartz’s nomination. With Republicans holding a 12-11 majority, any defection by a Republican member combined with unanimous Democratic opposition would block her advance to the full Senate floor. Schwartz must secure at least one Democratic vote or unanimous Republican backing to move forward—a threshold her performance on Wednesday may have made harder to reach.